Volitionrx LTD (VNRX)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $0.18
- As of
Kresmion compiles this page from VNRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
VOLITIONRX LTD (VNRX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-25.
See the full VNRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VNRX on one page. Preview it with sample data, then open it live with a free account.
Preview the VNRX dossierActive signals for VNRX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 45.2%, EPS $-0.85 vs $-0.5855 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 17.6% - EPS $-1.2 vs $-1.02 estimate
- mediumEARNINGS_MISS
Missed consensus by 17.6% - EPS $-1.2 vs $-1.02 estimate
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 11.4% - EPS $-1 vs $-0.8976 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 22.3% - EPS $-1.04 vs $-0.8501 estimate
FREE, NO ACCOUNT
Every signal on VNRX, as it fires
You are seeing 5 of 6 signals recorded on VNRX since 2026-05-17.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, VNRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VNRX against its peers
VNRX's operating margin of -1258.5% ranks in the 19th percentile of 12 Medical Devices sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | VNRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.7M USD | 3.0M USD | 38 | 16 |
| Gross margin | n/a | 42.6% | n/a | 14 |
| Operating margin | -1258.5% | -141.2% | 19 | 12 |
| Net margin | -1352.2% | -152.1% | 23 | 14 |
| Return on equity | n/a | -156.4% | n/a | 14 |
| 1 year | -98.0% | -83.8% | 4 | 12 |
Peers (19): ICCM, WOK, CODX, AMIX, NVNO, INBS, VVOS, BMRA, AEMD, TNON, USAQ, STME, AIDX, CTSO, NXL, IRIX, ALRTF, ADGM, TANAF. Left out: CYDX (no annual filing), KLYG (no annual filing), SONX (period gap), NMTC (no annual filing), TRIB (period gap), PMEDF (period gap). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VNRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VNRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VNRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.